ClinConnect ClinConnect Logo
Search / Trial NCT03030690

A Clinical Assessment of Glass Carbomer Cement

Launched by KING ABDULAZIZ UNIVERSITY · Jan 21, 2017

Trial Information

Current as of August 02, 2025

Completed

Keywords

Proximal Dental Caries Glass Carbomer Hydroxyapatite Enhanced Glass Ionomer Primary Teeth

ClinConnect Summary

Glass Carbomer is a monomer free; carbomised nano-glass restorative cement developed from traditional glass ionomer cement (GIC) and contains nano-sized powder particles of hydroxyapatite and fluorapatite. These materials claim to have improved mechanical properties and better bonding to dentin, in addition to continues fluoride release.

The study is a randomized controlled clinical trial where teeth will be randomly assigned to one of the three restoration groups.

Following medical and dental history, bilateral bitewing radiographs will be taken for each patient to assess the presence of...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • One proximal lesion in a primary molar.
  • Radiographic evidence of caries extending at least into the inner half of the enamel but not the inner half of dentin.
  • Proximal contact with adjacent healthy or restored teeth.
  • Occlusal contact with opposing healthy or restored teeth.
  • No indication for pulp therapy or other restorative treatment.
  • A predicted survival until exfoliation of 2 years.
  • Exclusion Criteria:
  • Radiographic evidence of caries extending into the inner half of dentin.
  • No proximal contact with adjacent healthy or restored teeth.
  • No occlusal contact with opposing healthy or restored teeth.
  • Tooth indicated for pulp therapy or other restorative treatment.
  • A predicted survival until exfoliation of less than 2 years.

About King Abdulaziz University

King Abdulaziz University (KAU) is a leading academic institution located in Jeddah, Saudi Arabia, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, KAU leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving healthcare outcomes. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and industry partners, ensuring adherence to rigorous ethical standards and regulatory requirements. KAU is dedicated to enhancing scientific knowledge and translating research findings into practical applications that benefit patients and the broader community.

Locations

Patients applied

0 patients applied

Trial Officials

Najlaa Alamoudi, MSc, DSc

Study Chair

King Abdulaziz University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials